MicroRNAs are key regulators of gene expression and play critical roles in both normal physiology and pathology. Recent research has demonstrated that these molecules are present in body fluids, such as serum, plasma, and urine, and can be readily measured using a variety of techniques. More importantly, emerging evidence suggests that circulating or urine miRNAs are useful indicators of disease. Here, we consider the potential utility of such miRNAs as noninvasive biomarkers of prostate cancer, a disease that would benefit substantially from novel diagnostic and prognostic tools. The studies aimed at identifying diagnostic, prognostic, and/or predictive miRNAs for prostate cancer are summarised and reviewed. Finally, practical considerations that will influence the translation of this recent research into clinical implementation are discussed.
Written by:
Sapre N, Selth LA. Are you the author?
Department of Surgery, Royal Melbourne Hospital, The University of Melbourne, Level 5 Clinical Sciences Building, Parkville, Melbourne, VIC 3050, Australia.
Reference: Prostate Cancer. 2013;2013:539680.
doi: 10.1155/2013/539680
PubMed Abstract
PMID: 23577261
Go "Beyond the Abstract" - Read an article written by the authors for UroToday.com
UroToday.com Investigative Urology Section
